Ikarian Capital’s C4 Therapeutics CCCC Stock Holding History
Bought
Maintained
Sold
Other funds holding CCCC
LCM
Ikarian Capital's CCCC Position: Q3 2026 in Review
Ikarian Capital reduced its C4 Therapeutics (CCCC) stake by 21% in Q3 2026, selling an estimated $1.86M and leaving 1,933,000 shares worth $6.44M. The position accounts for 0.65% of the portfolio, ranked #39.
Ikarian Capital first reported a position in CCCC in Q4 2020 and has held it in 5 quarters since. The position peaked at $11.4M in Q2 2026. 146 funds tracked by Wall St. Rank hold CCCC as of Q3 2026.
- Ikarian Capital held 1,933,000 shares of C4 Therapeutics worth $6.44M as of Q3 2026.
- Ikarian Capital sold 500,000 C4 Therapeutics shares in Q3 2026, an estimated $1.86M.
- C4 Therapeutics made up 0.65% of Ikarian Capital's portfolio in Q3 2026, its #39 holding.
- Ikarian Capital first reported a position in C4 Therapeutics in Q4 2020 and has held it in 5 quarters since.
- Ikarian Capital's C4 Therapeutics position peaked at $11.4M in Q2 2026.
- 146 funds tracked by Wall St. Rank held C4 Therapeutics as of Q3 2026.
Based on Ikarian Capital's 13F filing for Q3 2026, filed 16 Nov 2026.